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Abstract 
Matrix-Assisted Laser Desorption and Ionization Time-of-Flight Mass  
Spectrometry (MALDI-TOF MS) has been revealed as an invaluable platform for 
identifying anaerobic bacteria in the clinical laboratory over traditional methods such as 
the RapID ANA II System. 
A qualitative comparison is made, through the analysis of methodologies and 
specifications, to determine whether the RapID ANA II system or Bruker MALDI-TOF 
MS is more suitable for identifying anaerobic organism in the clinical laboratory. Based 
on the data reviewed, the MALDI-TOF MS is a more intuitive platform within the clinical 
laboratory due to its increased specificity, cost-effectiveness, and shorten turnaround 
time for the identification of anaerobes.  
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Introduction 
Anaerobic bacteria grow in the absence of oxygen. The major types of 
anaerobes are obligate anaerobes, facultative anaerobes, and aerotolerant anaerobes. 
Obligate anaerobes only grow in the absence of oxygen. Facultative anaerobes do not 
require oxygen to grow but will use it if available. Aerotolerant anaerobes grow best 
without oxygen but can tolerate its presence. Anaerobes are part of the normal flora 
found on the human body. Under normal circumstances, anaerobic bacteria live on the 
body as beneficial commensals. The major sources of anaerobes are situated in the 
mouth, mucosal membrane surfaces, gastrointestinal and genital tracts.[1]  
Prevotella and Peptostreptococcus species, which are part of our normal 
anaerobic gram-negative and gram-positive oral flora, have characteristics to protect the 
human body. [2] In a study conducted on children with a history of group A β-hemolytic 
streptococci (GABHS) pharyngotonsillitis, children with less Prevotella and 
Peptostreptococcus anaerobes cultured from their tonsils have an increased likelihood 
of having recurring GABHS infections than children with more of these anaerobes.[2] 
This phenomenon is known as bacterial interference and colonization resistance. [2,3] 
However, in humans with immunocompromised status, trauma or disease, GABHS 
infections may lead to serious anaerobic infections or death. [3] Therefore, it is 
imperative that the laboratory can identify anaerobes accurately and timely.  
 A specimen must be obtained before anaerobes can be identified. Due to the 
fastidious nature of anaerobes, it is often difficult to culture and grow them if collection 
techniques are not properly followed. [4] Some anaerobes are killed within seconds once 
they encounter molecular oxygen. [5] Therefore, using proper collection techniques is 
2 
 
 
important to enhance anaerobic growth with better outcomes. When anaerobes are 
stored in room temperature with the appropriate anaerobic transport tube, anaerobes 
will survive 24 to 72 hours. However, the survival of certain species of anaerobes is 
greatly diminished after 48 hours. [5] As a result, the ability to rapidly identify the correct 
type of anaerobic bacteria is extremely important when treating patients with anaerobic 
infections.  
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Methods  
 Given the need for the rapid identification of anaerobes, different tools have been 
developed to aid laboratorians in identifying anaerobes. The “golden standard” for 
identifying bacterial species is using whole-genome sequencing (WGS) and 16S 
ribosomal ribonucleic acid (rRNA) gene sequencing. [6,7] However, due to the cost and  
lengthy turnaround time of sequencing, these two methods are not the ideal options for 
identifying anaerobes in the clinical laboratory. At present, Remel RapID ANA II and the 
Bruker MALDI-TOF MS appear to be the most commonly used methods in anaerobic 
identification. A qualitative comparison is conducted to determine which of these two 
methods is more desirable for identifying anaerobic organism in the clinical laboratory 
via thorough analysis of their methodologies and specifications. 
Remel RapID ANA II System 
The Remel RapID ANA II system is a chromogenic, single sub-substrate 
qualitative method using enzyme technology tests to identify clinically significant 
anaerobes from human specimens. The assay is comprised of a plastic disposable 
RapID panel with ten reaction cavities, RapID inoculation fluid, RapID ANA II reagent, 
and RapID Spot Indole reagent. The test organism must first be dispensed into the 
RapID inoculation fluid prior to the inoculation of the cavity. After the inoculation of the 
panel,  the organism must be incubated for 4-6 hours. Upon the completion of 
incubation, reagents must be added into underlined wells to produce a colorimetric 
change which indicates the presence of enzymes. The resulting pattern must then be 
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entered into an Electronic RapID Compendium (ERIC) database used to identify the 
anaerobic bacteria.[8] 
Matrix-Assisted Laser Desorption and Ionization (MALDI) System  
The MALDI is an ionization technique that uses a matrix to form ions from larger 
molecules for molecular identification. [11] First, the user must transfer a bacterial colony 
grown from a patient sample (which is first mixed with or without formic acid depending 
on the organism being identified) onto a MALDI “target” plate. The bacterial isolate is 
then embedded with the matrix for protein extraction. [12,13] Figure 1 below depicts the 
preparation of a sample plate for sample analysis (Clark et al., 2013). After the isolate 
embedded with the matrix is dried, the plate is inserted into the ionization assembly of 
the instrument. A nitrogen laser with a wavelength of 337 nm then heats the matrix 
embedded sample rapidly, causing the sample to vaporize into ions. The ions 
subsequently enter the mass spectrometer for identification. [14,15]  
 
Figure 1 Schematic for the preparation of MALDI-TOF MS plate for sample identification. Growth from the 
sample culture is applied to target slide and overlaid with matrix. Once dried, it is ready for instrument 
anaylsis. (Clark et al., 2013)  
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The mass spectrometer used in this assay is Time-of-Flight Mass Spectrometry 
(TOF MS). In this stage, charged ions from the vaporized sample are divided based on 
their mass-to-charge ratio (m/z). Smaller ions with a greater charge will reach the 
detector quicker than larger ions with a smaller charge. [14] The detected biomolecules 
generate a spectrum that is matched with a database of known organisms. The 
matching provides a confidence level which aids in the identification of the sample. [15]  
The detailed steps of the MALDI-TOF MS is presented in  Figure 2 below  (Croxatto et 
al., 2012) . [16] 
 
Figure 2 Identification process via the MALDI-TOF MS system. Matrix-embedded sample is introduced 
into a mass spectrometer where a laser strikes the sample resulting in vaporized ions. The ions enter a 
flight tube where they are sorted based on mass-to-charge charge ratio (m/z) and read by the detector. A 
spectrum is then generated that is matched with a database of known organisms. (Croxatto et al., 2012)  
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The Bruker Biotyper system generates a confidence score between 0.00-3.00, 
indicating the identification confidence of the organism being analyzed. A score of 2.00-
3.00 (green) indicates a high degree of confidence, 1.70-1.99 (yellow) reflects a low 
degree of confidence, and below 1.70 (red) means no identification.  
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Results  
RapID ANA II System 
Research has shown that the accuracy of the RapID ANA II manifested  
discrepant results for anaerobic identification. In a performance study conducted by 
Marler et al., the RapID ANA II test was thoroughly evaluated for its ability to identity 
566 anaerobes. The successful rates of identifying correct species under this method 
are summarized in Table 1 below:  
  
Isolate 
 
Correct identification (% of total) 
Gram-negative bacilli 62% of 204 
Nonsporeforming gram positive bacilli 70% of 69 
Clostridium isolates 74% of 130 
Anaerobic cocci 72% of 163 
Table 1 Identification assessment of 566 anaerobes using the RapID ANA II test, adapted from 
“Evaluation of the new RapID-ANA II system for the identification of clinical anaerobic isolates,” Marler et 
al., J. Clin. Microbiol. 29: 874-878.  
The RapID ANA II kit performed well with spot indole negative Bacteroides 
fragilis group, correctly identifying 26 of 28 (93%) isolates. All strains of Parabacteroides 
distasonis as well as 19 of 27 (70%) of Bacteroides vulgatus were also accurately 
identified. On the contrary, the spot indole positive Bacteroides fragilis group proved 
problematic with the RapID ANA II panel. For Bacteroides ovatus and Bacteroides 
uniformis, 1 of 29 (3%) and 4 of 14 (29%) were correctly identified, respectively. 
Bacteroides ovatus was often confused with Bacteroides uniformis along with 
Bacteroides thetaiotaomicron. [9,10] Overall, the RapID ANA II system correctly identified 
approximately 68% of the 566 anaerobic isolates to the genus and species level. [9]   
The limitations of the RapID ANA II system should be carefully assessed 
when using this method in the clinical laboratory. The technologist must ensure that  
8 
 
 
pure culture isolates with enough colonies be used to achieve a #3 McFarland standard, 
and the RapID ANA II tray be incubated between 4-6 hours at 35-37°C. Setting up the 
test outside of the manufacturer’s instructed parameters or using a mixed culture may 
lead to misidentification. [8] Additionally, the technologist must have adequate 
knowledge of anaerobes to resolve discrepant results as well as sufficient access to 
additional tests that may help identify each isolate. Additional tests (including gram 
staining, aerotolerance, specimen source, and growth on selective agars) should be 
used in conjunction with the RapID ANA II system. [8] 
Bruker MALDI-TOF MS System 
 Numerous studies indicated that Bruker MALDI-TOF MS is a robust platform 
which allows users to identify anaerobic organisms with a high level of confidence. In a 
study conducted by Schmitt et al. in 2012, this system was evaluated for its capability to 
correctly identifying 252 clinical isolates of anaerobic bacteria (see Table 2 below).  
 
 Total Isolates Species identification Genus identification No identification 
               252 179 (70.8%) 232 (91.7%) 20 (7.9%) 
Table 2 Evaluation of 252 clinical isolates of anaerobic bacteria using Bruker MALDI-TOF MS, adapted 
from “Identification of Anaerobic Bacteria by Bruker Biotyper Matrix-Assisted Laser Desorption and 
Ionization-Time of Flight Mass Spectrometry with On-Plate Formic Acid Preparation,” Schmitt et al., 
Journal of Clinical Microbiology,51(3), 782-786.  
The anaerobes were identified using Bruker’s cut-off values. A total of 179 
(70.8%) and 232 (91.7%) of anaerobic isolates were identified correctly to the genus 
and species level using the manufacturers cut-off scores. Twenty (7.9%) of the clinical 
isolates had no identification because they received a score below 1.70. [18] This study 
demonstrated that using the Bruker Biotyper was a great alternative for identifying 
anaerobic bacteria.  
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In a subsequent study involving a larger collection of anaerobes for the  
evaluation of the Bruker Microflex LT mass spectrometer equipped with the MALDI  
Biotyper 3.0 software, the results achieved were even more promising. Barreau et al., 
conducted a study with 1,325 anaerobes to determine the capability of the Bruker MS. 
The isolation of anaerobic specimens was from blood culture (362), abscesses and 
liquid collection (287), tissue samples (319), osteo-articular samples (144), sinus 
samples (115), lymph nodes (21), cerebral spinal fluid (20), pleural samples (32) and 
other samples (25). [19] The Bruker MS correctly identified 92.5% of isolates to the 
species level and 98.9% identified to genus level. 14 of the 1325 samples could not be 
identified to the genus level. [19] Table 3 below summarizes the findings from the study. 
Barreau et al. stated that the improvements in identification were due to software 
upgrades. Barreau et al. further pointed out that this method should be considered the 
new gold standard for the routine identification of clinical anaerobes.  
  
Total Isolates 
Species 
identification 
(score ≥ 1.9) 
 
Genus identification 
(score <1.9 ≥ 1.7) 
 
No identification 
(Score < 1.7) 
1,325 1,225 (92.5%) 86 (6.5% genus only) 14 (1.0%) 
Table 3 Evaluation of the Bruker MALDI-TOF MS with Biotyper 3.0 software for the identification of 1,325 
anaerobic isolates, adapted from “Improving the identification of anaerobes in the clinical microbiology 
laboratory through MALDI-TOF mass spectrometry,” by Barreau et al., 2013, Anaerobe 22, 123-125. 
Copyright by 2013 Elsevier Ltd.  
The MALDI-TOF MS must be validated to ensure it produces reliable and 
reproducible results before implementing it within the clinical laboratory. To properly 
validate this platform, the laboratory must follow the regulatory guidelines established by 
the College of American Pathologists (CAP) and the Clinical Laboratory Improvement 
Amendments (CLIA) for method validation.  
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According to CAP All Common Checklist, a minimum of 20 samples should be 
tested. [20,21] Likewise, CLIA suggests a minimum of 20 samples to be run for method 
validation. However, majority of other sources suggest running at least 40 specimens to 
detect discrepancies. Ideally speaking, method validation should be performed over a 
period of five days with a confidence score of at least 90%. However, if discrepancies 
are observed, the validation should be extended for five more days. [22] 
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Discussion 
 Cost effectiveness is a key consideration when incorporating a new platform in 
the clinical laboratory. The new method should yield a positive return of investment, 
allowing resources and personnel to be allocated elsewhere in the department for 
quality improvements. When comparing the two platforms discussed earlier (see Table 
4 below), the cost per test and versatility of each method should be carefully analyzed. 
 
RapID ANA II Bruker MALDI-TOF MS 
Turnaround time 4-6 hours ~15 minutes 
Accuracy 68% to genus and species 92.5% to genus and species 
Cost $9.19/test $0.50/test 
Table 4 Comparison of the RapID ANA II and Bruker MALDI-TOF MS based on turnaround time, 
accuracy, and cost-effectiveness.  
The Department of Veteran Affairs lists a 20 pack RapID ANA II kit for the price 
of $152.16. [23] The kit includes the ANA II reagent but does not include the spot indole 
or RapID inoculation fluid that must be purchased separately. The rapid spot indole 
reagent is listed for $11.12, and the RapID inoculation fluid costs $20.43 for a pack of 
20. [23] The price of the Bruker MALDI-TOF MS costs $150,000. [24] In addition, the 
Bruker requires additional consumables to run a sample. The consumables required to 
operate the MALDI TOF MS are pipette tips, target slides, matrix, and formic acid. 
When we factor in the RapID ANA II kit with the spot indole reagent, the cost is $9.19 
per test. Using the MALDI-TOF MS; however, only costs $0.50 per test with a much 
higher level of accuracy in identification (92.5% with Bruker vs. 68% with RapID) [24,25] 
This data shows that the clinical laboratory could run 18 anaerobe samples with 
MALDI-TOF MS for the cost of running one sample with RAPID ANA II. In addition, the 
test under RapID ANA II requires the kit to be incubated for 4 hours, applying reagents, 
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interpreting of each enzymatic test, and entering enzyme results into the ERIC database 
for identification. In contrast, the MALDI-TOF MS can identify a sample in approximately 
15 minutes. [25] 
 The savings of incorporating MALDI-TOF MS are more profound than what have 
been discussed earlier. In a study conducted in a Taiwanese laboratory from July to 
December 2012, 52,500 isolates were analyzed (47,300 aerobes and 5,200 
anaerobes). This study revealed a bi-annual savings of $84,000 compared to 
conventional biochemical methods. [26] If the 5,200 anaerobes were to be identified 
using RapID ANA, it would cost $42,284 compared to $2,600 using the MALDI-TOF 
Apparently, MALDI-TOF MS is much more versatile than RapID because the former 
could also identify yeast and aerobic organisms; thereby, significantly improving the 
financial health of the entire laboratory.  
In a study conducted by the University of North Carolina Hospitals from April 
2013 to March 2014, using MALDI-TOF MS could realize an annual savings of $73,646, 
which would compensate for the cost of the equipment within 3 years. [27] Nevertheless, 
cost savings also depend on the volume received at each laboratory, with larger 
institutions being able to offset the cost of the instrument much quicker.  
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Conclusion 
 The Bruker MALDI-TOF MS provides a more robust platform for identifying 
anaerobes within the clinical laboratory due to the following factors:  
• Identification of anaerobes can be efficiently accomplished within 15 minutes since it 
does not require an aerotolerance test. The quicker turnaround time allows clinicians 
to treat patients more effectively and reduce the duration of hospital visits. In 
contrast, the RapID ANA II method recommends a 24-hour aerotolerance test and 
an additional 4-6 hours of incubation for identification. 
• MALDI-TOF MS offers 18 times more savings than RapID ANA II, costing $0.50 
compared to $9.19 per test and with a much higher successful rate in identification.  
• Bruker’s database of organism continues to expand through software upgrades, 
which allows for the timely detection of anaerobic organisms with increased 
accuracy.  
• Numerous studies have shown that MALDI-TOF MS is more sensitive and specific 
than conventional methods for identifying anaerobes.  
In conclusion, MALDI-TOF MS has emerged as a superior method of 
identification over the RapID ANA II system within the clinical laboratory. The advent of 
MALDI-TOF MS has demonstrated increased specificity, cost-effectiveness, and 
decreased turnaround time. Due to the infancy of MALDI-TOF MS, it may require an 
alternative method of identification for confirmation, such as 16S RNA and WGS 
sequencing. However, research has proven the MALDI-TOF MS is capable of 
continuous improvements through a growing database. The MALDI-TOF MS has 
flourished in the clinical laboratory for the routine identification of anaerobes. 
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Isolates 
Species identification  
(score ≥ 1.9) 
Genus identification  
(score < 1.9 ≥ 1.7) 
 
Actinobacteria (417) 387 (92.3%) 30 (7.7%) 
Propionibacterium (375) 350 (96.9%) 25 (7.1%) 
Atopobium (7) 7 (100%)  
Bifidobacterium (8) 6 (75%) 2 (15%) 
Eggerthella (10) 8 (80%) 2 (20%) 
Slackia exigua (12) 12 (100%)  
Actinobaculum (4) 3 (75%) 1 (25%) 
Brevibacterium frigotolerans (1) 1 (100%)  
Clostridiales (343) 314 (90.8%) 29 (9.2%) 
Anaerotruncus colihominis (1) 1 (100%)  
Finegoldia (98) 86 (86.1%) 12 (13.9%) 
Peptostreptococcus (9) 9 (90%) 1 (10%) 
Anaerococcus (32) 24 (66.7%) 8 (33.3%) 
Parvimonas (82) 77 (93.5%) 5 (6.5%) 
Peptoniphilus (66) 65 (98.5%) 1 (1.5%) 
Clostridium (43) 41 (95.1%) 2 (4.9%) 
Tissierella praeacuta (1) 1 (100%)  
Bilophila wadsworthia (3) 3 (100%)  
Dialister microaerophilus (2) 2 (100%)  
Eubacterium (3) 3 (100%)  
Ruminococcus gnavus (2) 2  
Lactobacillus (12) 12 (100%)  
Fusobacterium (86) 76 (86.9%) 10 (13.1%) 
Bacteriodales (442) 425 (96%) 17 (4%) 
Porphyromonas (17) 14 (78.6%) 3 (21.4%) 
Bacteroides (299) 292 (97.6%) 7 (2.4%) 
Parabacteroides (11) 11 (100%)  
Prevotella (80) 74 (91.9%) 6 (8.1%) 
Veillonella (29) 29 (100%)  
Alistipes finegoldii (1) 1 (100%)  
Butyricimonas (4) 3 (75%) 1 (25%) 
Odoribacter splanchnicus (1) 1 (100%)  
Erysipelotrichales (9) 9 (100%)  
Solobacterium moorei (8) 8  
Turicibacter sanguinis (1) 1  
Proteobacteria (2) 2 (100%)  
Desulfovibrio (2) 2 (100%)  
Overall (1311) 1225 (92.5%) 86 (6.5%) 
Table 5 Identification of 1,311anaerobe isolates at the genus and species level using the Bruker MALDI-
TOF MS, adapted from “Improving the identification of anaerobes in the clinical microbiology laboratory 
through MALDI-TOF mass spectrometry,” by Barreau et al., 2013, Anaerobe 22, 123-125. Copyright by 
2013 Elsevier Ltd.  
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